depends on a medical doctor's subjective judgment. Therefore, almost all of the diagnostic tests of HAVS are very subjective. There are few objective tests for diagnosing the HAVS at present, and good diagnosis method is required globally 2) .
Chromosomal aberration, micronuclei and sister chromatid exchanges (SCE) have been observed in physical exposure conditions, such as ionizing radiation and short wave ultraviolet radiation. A particular study which assessed in vitro cytogenetic effects of exposure to lowvibration regimes failed to detect an increase in SCE frequency in peripheral blood lymphocytes [4] [5] [6] . Occupational exposure to whole-body vibration and low frequency noise may have genotoxic effects in humans expressed as an increase in sister chromatid exchange levels in lymphocytes. These results also suggest a reason for the high incidence of malignancy in vibro-acoustic disease (VAD) patients [7] [8] [9] . The observed effects may not reflect a direct action of these physical characteristics on DNA. On the other hand, gene expression was used to assess the effects of exposure to vibration stress or noise on hearing loss 10) . Genome-wide expression profiling by cDNA microarray is a powerful technique for monitoring changes in gene expression. This technology can be utilized to study nearly every known biological process and in the future will yield a large volume of biologically significant information. An important application of this technology is the study of gene expression changes that occur under normal and pathological conditions. Although there are plenty of investigations into the pathogenesis of HAVS, the molecular mechanism of the pathogenesis of HAVS is still unknown and there are no sensitive and specific objective methods for its diagnosis.
In this pilot study, the potential of cDNA microarray analysis of gene expression of HAVS patients was investigated.
Ethical permission was obtained from the Research Ethics Committee of the Japan National Institute of Occupational Safety and Health. Seven men with HAVS secondary vibration white finger disease (median age 61.3 yr, range 38-72 yr) and 3 healthy men (median 52.2 yr, range 37-72 yr) were enrolled into the study. The ten subjects were all volunteers, and they gave their written informed consent. No patient or control subject was taking medication at the time of study. The mean duration of Raynaud's Phenomenon (RP) was 10.8 yr (range 2-20 yr). The characteristics of the patients are shown in Table 1 .
Subjects s5, s7 and s10 had clinically more severe symptoms than subjects s1, s3, s4 and s6 according to the results of the Vascular Test and the Stockholm Workshop Scale 2) . Subjects s7 and s10 have Raynaud's disease, and the Ministry of Health, Labour and Welfare have designated these subjects as HAVS patients. Although these subjects have not used hand-held tools many years, they still have vibration syndrome as evidenced by recent test results, which were obtained at the health examination for all subjects in 2002 (Table 1) .
A 10-ml blood sample was taken from the antecubital fossa using a 19-gauge needle. The pressure was released for at least 10 s before the blood was drawn. Blood was collected into tubes containing anticoagulant heparin and Trizol-LS (Invitrogen, Carlbad, CA, USA). A reagent containing RNase inactivator, was added immediately and this blood sample was used for total RNA purification. Total RNA was extracted from blood samples using Trizol-LS according to the manufacturer's protocol. Whole blood instead of the leukocytes was used for the purification of RNA, since RNA molecules may degrade during the isolation of leukocytes. Great care was taken during the purification of RNA to use RNase-free reagents and to perform all the procedures in a space used exclusively for RNA experiments. The cDNA probes were prepared by reverse transcription with Cy3-dUTP (Amersham, Piscatway, NJ USA) from the RNAs using a labeling kit (Invitrogen). Hybridization and washing of the microarray were carried out by a microarray company (DNA Chip Research Inc., Yokohama, Japan), and the quality of the labeled cDNA was checked and confirmed as suitable for the experiment by this commercial company before hybridization. All blood samples were obtained in the morning in one visit after a standard light breakfast. We performed the microarray analysis with the Human CHIP version 1 (DNA Chip Research Inc., Yokohama), on which 2,976 genes were spotted. These genes were selected from a cDNA library prepared with the human peripheral white blood cells (WBC). Also on the chip, six kinds of internal controls, human transaldolase, human ribosomal protein S9, human histone (H2A.Z), human beta-actin, human phospholipase A2, and human elongation factor-1-beta, were included in 12 of the 48 blocks. Spots with brighter fluorescence mean that the genes are expressed in higher degree in the subjects.
A hierarchical clustering analysis was conducted using average linkage and elucidation dissimilarity for the significant genes using MEV software 11, 12) . For gene ontology analysis of the altered gene expressions in the HAVS patients, we used DAVID 2.0, a comprehensive set of software tools for visually summarizing annotation from large lists of genes 13) . The significance of different expressed genes level, between the HAVS patients and controls, was computed using the randomized variance model 14) . The volcano plot provides a summary of test statistics for different level of gene expression between HAVS patients and the controls.
Cluster analysis of the ten subjects is shown in Fig. 1 . Only the genes with expression of 2-fold or more were included in the analysis (there was no gene with 0.5-fold or less down-regulated in this experiment).
Our analysis demonstrates that there were distinct gene expression patterns between the HAVS patients and the control subjects. The mean shown in Fig. 1 was calculated as an arithmetical mean among patients' gene expression in the same group. As shown in Fig. 1 , it is clear that in the control subject group (s2, s8, s9) there was a tendency of lower expression of the genes highly expressed in the HAVS patient group. The increase in the gene expression was most significant in three HAVS patients, s5, s7, and s10, when compared to the control group and other patients. Among these three patients, s7 and s10 have Raynaud's disease. Patients s3, s1, s4 and s6 showed higher gene expressions than in the control subjects, but lower than in the group of s5, s7 and s10. Patient s6 was also diagnosed as having Raynaud's disease and showed a generally high level of gene expression. Overall, gene expression in the group of s5, s7, s10 was the highest, followed by that in the group of other HAVS patients, and that in the control group was the lowest. These results show clear differences in the gene expression levels between groups, i.e., group (s5, s7, s10) with the vascular diseases such as vibration-induced white finger, group (s1, 23, s4, s6) with the sensorineural diseases such as a reduced sensory perception, and the control group (s2, s8, s9) without HAVS, suggesting the possible application of gene expression profiling to the detection and evaluation of HAVS. Table 2 shows the genes with expressions of 2-fold or more in HAVS subjects over controls from summarized by possible biological process category. These genes are involved in the metabolism of cell membrane structure, cell or DNA replication and repair, inflammatory response, energy metabolism etc., and possibly represent the complicated pathological processes of HAVS.
In this pilot study, we investigated the gene expression in the peripheral blood of HAVS patients and controls by microarray analysis, and the following results were obtained. 1: There were distinct gene expression patterns between the HAVS patients and the control subjects. 2: Genes related to vascular disease, such as vibrationinduced white finger, were among those identified as having different expression patterns. 
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Intermittent or persistent numbness, reduced tactile discrimination and/or manipulative dexterity sensory perception, were also among those identified. 4: Genes that are up-regulated in HAVS were also identified and this will be useful for further understanding the processes of HAVS occurrence. Only a small number of subjects were included in this study, and further study needs to examine a large number of subjects with HAVS patients at different stages to validate the gene or protein biomarkers of HAVS patients.
Previously, no research has been carried out like this pilot study, with regard to searching for an objective diagnosis approach to HAVS, and no solution has been presented to resolve this problem. The results of our study suggest the potential application of gene expression profiling in the diagnosis and evaluation of HAVS patients. 
